Clinical significance of serum anti-CABP detection in patients with inflammatory bowel disease
10.3760/cma.j.cn101480-20200423-00045
- VernacularTitle:炎症性肠病患者血清中anti-CABP水平检测的临床意义
- Author:
Yarong WEI
1
;
Tingting CHEN
;
Wu YANG
;
Huihui LI
;
Chen FANG
;
Wei HAN
;
Xiaochang LIU
;
Qiao MEI
Author Information
1. 安徽医科大学第一附属医院消化内科 安徽省消化疾病重点实验室，合肥 230022
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Crohn′s disease;
Ulcerative colitis;
Anti-Crohn′s disease antibody binding polypeptide;
Antibodies, anti-neutrophil cytoplasmi
- From:
Chinese Journal of Inflammatory Bowel Diseases
2021;05(1):55-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical significance of anti-Crohn′s disease antibody binding polypeptide (anti-CABP) in the diagnosis of inflammatory bowel disease (IBD) .Methods:Clinical data of 190 IBD patients diagnosed in the First Affiliated Hospital of Anhui Medical University from June 2017 to December 2019 were analyzed prospectively, including 103 patients with Crohn’s disease (CD) and 87 patients with ulcerative colitis (UC) . And 107 patients with gastrointestinal polyposis were set as control group. The serum level of anti-CABP, anti- Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) were detected in CD, UC and control groups by using ELISA. The differences in the serum level and positive rates of anti-CABP, ASCA and pANCA among the three groups were analyzed statistically. The diagnostic value of anti-CABP was evaluated by using receiver operating characteristic (ROC) analysis. The correlation between anti-CABP and clinical characteristics of IBD was analyzed. Results:The levels of anti-CABP IgA[14.46 (7.77, 34.71) U/ml vs. 10.22 (5.71, 14.98) U/ml and 6.60 (5.04, 8.38) U/ml, both P<0.01], anti-CABP IgG [11.12 (4.48, 42.31) U/ml vs. 5.26 (3.28, 10.02) U/ml and 2.85 (2.41, 3.52) U/ml, both P<0.01] and ASCA IgG[5.59 (2.68, 11.36) U/ml vs. 2.63 (1.42, 6.40) U/ml and 2.19 (1.20, 4.03) U/ml, both P<0.01] of CD patients were significantly higher than those of UC patients and control group. The pANCA level in UC patients was significantly higher than that of CD and control groups [8.55 (4.06, 19.98) U/ml vs. 2.91 (2.09, 3.99) U/ml and 1.65 (1.24, 2.23) U/ml, both P<0.01]. The positive rate of anti-CABP was 45.63% in CD patients, which was obviously higher than 4.60% in UC patients ( P<0.01) . Anti-CABP could effectively distinguish CD from non-CD patients (AUC 0.840) , and the diagnostic efficacy of anti-CABP was better than that of ASCA (AUC 0.708) . The combined use of three antibodies (anti-CABP, ASCA and pANCA) significantly improved the diagnostic value and the AUC was 0.892. The positive rate of anti-CABP IgA was not related with the clinical characteristics of IBD (all P>0.05) , while the positive rate of anti-CABP IgG was significantly different in the disease locations of CD patients ( P = 0.016) . Conclusion:The positive rate of anti-CABP in CD patients is significantly higher than that in UC patients, which suggests that the anti-CABP can be used as a serological marker to assist diagnosis and differential diagnosis of CD.
